Introduction
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2024, approximately one quarter of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its three lead ADCs are Enhertu (HER2), Datroway (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first US approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.
Information is being updated
You need to login to view information
Charter capital
Business Size and Operations
Company Size
Total Assets
| A10 (Bellow 100 B) | A9 (100 - 200 B) | A8 (200 - 400 B) | A7 (400 - 600 B) | A6 (600 - 800 B) |
| A5 (800 - 1000 B) | A4 (1000 - 1500 B) | A3 (1500 - 2000 B) | A2 (2000 - 2500 B) | A1 (Above 2500 B) |
Owner’s Equity
| E10 (Bellow 100 B) | E9 (100 - 200 B) | E8 (200 - 400 B) | E7 (400 - 600 B) | E6 (600 - 800 B) |
| E5 (800 - 1000 B) | E4 (1000 - 1500 B) | E3 (1500 - 2000 B) | E2 (2000 - 2500 B) | E1 (Above 2500 B) |
Business Activities
Revenue
| R10 (Bellow 100 B) | R9 (100 - 200 B) | R8 (200 - 400 B) | R7 (400 - 600 B) | R6 (600 - 800 B) |
| R5 (800 - 1000 B) | R4 (1000 - 1500 B) | R3 (1500 - 2000 B) | R2 (2000 - 2500 B) | R1 (Above 2500 B) |
Number of employee
| L10 (Bellow 100 Peoples) | L9 (100 - 200 Peoples) | L8 (200 - 400 Peoples) | L7 (400 - 600 Peoples) | L6 (600 - 800 Peoples) |
| L5 (800 - 1000 Peoples) | L4 (1000 - 1500 Peoples) | L3 (1500 - 2000 Peoples) | L2 (2000 - 2500 Peoples) | L1 (Above 2500 Peoples) |
Company’s Market Position
Profitability within the Industry
Return on Total Assets (ROA)
| Bottom 25% | 25%-m | m-25% | Top 25% |
Return on Equity (ROE)
Net Profit Margin (ROS)
Current Ratio
| Bottom 25% | 25%-m | m-25% | Top 25% |
Total asset turnover
| Bosttom 25% | 25%-m | m-25% | Top 25% |